Drug Profile
Research programme: Hsp90 inhibitors - Isomerase Therapeutics
Alternative Names: BC 226; BC 274; BHI-001Latest Information Update: 08 Aug 2011
Price :
$50
*
At a glance
- Originator Biotica Technology
- Class Macrolides
- Mechanism of Action HSP90 heat-shock protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 08 Aug 2011 Hsp90 inhibitors programme available for partnering/licensing following completion of preclinical proof-of-concept studies. http://www.biotica.com
- 27 Jan 2011 No development reported - Preclinical for Cancer in United Kingdom (Parenteral)
- 10 May 2007 Data presented at the 98th Annual Meeting of the American Association for Cancer Research (AACR-2007) added to the pharmacokinetics and Cancer pharmacodynamics sections